| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_494981811887c035eeb4aa86f26c8536
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e89a8132ca8f7a60365a6d896fce7f6d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9d78a1a23dbbafd45a8ab8c03106c0ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ee8caf54b0fc3f1bd76c99ea045c2d33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dfcc0434437a0e71a92954099ea5948b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 |
| filingDate |
2008-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46689a765ae9fb57ee94cdc38fdab3ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0dc0504791b2b6e2df1e8ae0075de709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c55a0acf4139e40579b97b6c1fef633b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0af6813b6da342d0f70e032118f71756 |
| publicationDate |
2009-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2009124362-A1 |
| titleOfInvention |
Suppressor of the endogenous interferon- gamma |
| abstract |
The invention relates to suppressor of the endogenous human interferon-gamma (hlFN-γ) applicable in treatment of diseases associated with impaired activity of endogenous hlFN-γ, especially autoimmune diseases and for prevention of graft arteriosclerosis and rejection of organs in allograft transplanted patients. It is based on inactive analogues of the hlFN-γ with preserved affinity to the hlFN-γ receptor, genetically modified in the domain responsible for triggering the signal transduction pathway. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3381935-A1 |
| priorityDate |
2008-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |